Does Johnson & Johnson (JNJ) Talc Verdict Add To Its Legal Risk?
Johnson & Johnson (NYSE: JNJ) was found liable by a Louisiana jury in a high-profile talc-related mesothelioma case, adding a fresh verdict to its ongoing talc litigation. The jury decision centers on alleged asbestos exposure from Johnson & Johnson talc products and raises questions about potential future legal costs for the company. This verdict contributes to the broader legal overhang that investors weigh alongside Johnson & Johnson's core healthcare operations and balance sheet...
Yahoo2 days agoJNJ
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.
Yahoo2 days agoJNJ
Three Dividend Kings That Pay a 75-Year-Old $3,900 a Month: KO, JNJ, and PEP
Replacing nearly $47,000 a year in retirement income without touching principal sounds like a math problem, but the real trap is choosing the wrong yield tier and watching either your paycheck or your nest egg quietly shrink.
Yahoo2 days agoJNJ
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside
Alumis Inc. faces high biotech risk after a lupus trial setback, but envudeucitinib TYK2 potential remains. Click for more on ALMS stock.
SeekingAlpha2 days agoJNJ
GSK: Still One Of My Top Healthcare Picks
GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.
SeekingAlpha8 days agoJNJ
FDA Issues Early Alert On Abiomed Heart Pump Controller Purge Cassette Issue
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-heart-pump-controller-purge-cassette-issue-abiomed
Benzinga9 days agoJNJ
Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment
Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.
Benzinga10 days agoJNJ
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S
Yahoo13 days agoJNJ
HALO Stock Rises 36% in a Month: Here's What You Should Know
Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
Yahoo13 days agoJNJ
Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect
Stryker (SYK) rebounds with 9% organic growth in Q2 as key segments accelerate.
SeekingAlpha15 days agoJNJ
Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade
Johnson & Johnson secures FDA clearance for MONARCH QUEST 3 software, boosting robotic bronchoscopy accuracy with AI. new 3D imaging tools.
Benzinga16 days agoJNJ
EVP At Johnson & Johnson Exercises Options Worth $2.38M
On August 18, it was revealed in an SEC filing that Jennifer Taubert, EVP at Johnson & Johnson (NYSE:JNJ) executed a significant exercise of company stock options. What Happened: Taubert, EVP at Johnson &
Benzinga16 days agoJNJ
Wednesday's big stock stories: What’s likely to move the market in the next trading session
The S&P 500 fell for a third session as elevated bond yields and oil kept stocks under pressure Tuesday. Tune in to CNBC Wednesday for BlackRock's Rick Rieder.
CNBC16 days agoJNJ
How Much More Can Boston Scientific Stock Move After Losing Half Its Value?
Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.
Yahoo21 days agoJNJ
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concu
Yahoo22 days agoJNJ
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.
Benzinga22 days agoJNJ
Johnson & Johnson (JNJ) Stock Sees Modest Fair Value Lift After Analyst Target Increases
Price targets on Johnson & Johnson have been moving higher, with bullish analysts now citing a range from about US$260 to US$305. This shift is closely linked to recent Street commentary that highlights solid execution in new medicines and MedTech, along with reduced legal uncertainty around talc litigation. As you read on, you will see how these changing targets fit into the broader analyst narrative and what to watch to stay on top of the story. Stay updated as the Fair Value for Johnson &...
Yahoolast monthJNJ
J&J’s biotech progress could punish its 2027 profit
Johnson & Johnson (JNJ) just issued one of the weirdest profit warnings in health care. The biotech business decreased its 2026 adjusted earnings guidance to between $10.96 and $11.11 a share, from a range of $11.60 to $11.75. This year, the newly closed acquisition of Firefly Bio and the ...
Yahoolast monthJNJ
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.
Yahoolast monthJNJ
Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]
Yahoolast monthJNJ